Ovid Therapeutics (OVID) News Today $1.84 +0.20 (+12.20%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.79 -0.05 (-2.66%) As of 10/3/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is Ovid Therapeutics Up Today?Toggle Visibility of Why Is Ovid Therapeutics Up Today?Shares of Ovid Therapeutics (NASDAQ:OVID) climbed on Tuesday as investors reacted to a $175 million PIPE financing deal, encouraging Phase 1 data for its lead epilepsy candidate OV329, and rising market interest in the stock. Positive Sentiment: Ovid announced a private placement expected to generate up to $175.1 million in gross proceeds—initially $81 million—to fund R&D and operations into 2028. Ovid Therapeutics Secures $175.1M in Private Placement Positive Sentiment: Topline Phase 1 results for OV329 showed strong GABA-AT inhibition and a clean ocular safety profile, reinforcing its potential in treatment-resistant epilepsy. Ovid announces positive topline results Positive Sentiment: Call option volume surged to 3,750 contracts—up 347%—signaling heightened bullish betting on OVID shares. Ovid Therapeutics Sees Unusually Large Options Volume Positive Sentiment: Short interest fell by 61.5% in September, reducing bearish pressure on the stock. Ovid Therapeutics Sees Large Decrease in Short Interest Positive Sentiment: Analyst sentiment remains upbeat—five brokerages rate OVID a Buy (including one Strong Buy)—underscoring confidence in its pipeline. Ovid Therapeutics Given Average Recommendation of Buy Positive Sentiment: A Seeking Alpha piece highlighted OV329’s strong modulation of neuronal excitability, adding to the drug’s promise in neurological disorders. OV329 Promising For Neuronal Excitability Neutral Sentiment: Ovid scheduled a special investor webcast with management and analysts to discuss these updates, providing a forum for detail but no new data today. Ovid Therapeutics Inc. - Special Call Posted 23h agoAI Generated. May Contain Errors. OVID Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Ovid Therapeutics (OVID): Assessing Valuation Following Encouraging OV329 Phase 1 Trial Results1 hour ago | finance.yahoo.comStock Traders Purchase High Volume of Ovid Therapeutics Call Options (NASDAQ:OVID)October 4 at 2:45 AM | americanbankingnews.comOvid Therapeutics Secures $175.1M in Private PlacementOctober 3 at 5:31 PM | tipranks.comOvid Therapeutics: OV329 Promising For Neuronal Excitability In Neurological DisordersOctober 3 at 3:31 PM | seekingalpha.comOvid Therapeutics Sees Unusually Large Options Volume (NASDAQ:OVID)October 3 at 2:46 PM | marketbeat.comOvid Therapeutics prices private placement up to $175M in gross proceedsOctober 3 at 1:55 PM | msn.comOvid Therapeutics Inc. - Special CallOctober 3 at 1:02 PM | seekingalpha.comOvid Therapeutics stock soars after positive results for epilepsy drugOctober 3 at 8:54 AM | investing.comOvid Shares Leap Premarket on Positive Study Results, Financing PactOctober 3 at 8:54 AM | marketwatch.comOvid Therapeutics Shares Surge After Positive Epilepsy Drug Trial ResultsOctober 3 at 8:54 AM | msn.comOvid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in ...October 3 at 8:54 AM | finance.yahoo.comOvid Therapeutics Stock Rallied 18% Pre-Market – Here’s WhyOctober 3 at 8:54 AM | msn.comOvid Therapeutics Inc. Announces PIPE Financing Agreement Expected to Generate Up to $175 Million in Gross ProceedsOctober 3 at 7:30 AM | quiverquant.comQOvid Therapeutics Reports Positive Phase 1 Results for OV329, a Next-Generation GABA-AT Inhibitor for Drug-Resistant EpilepsiesOctober 3 at 7:30 AM | quiverquant.comQOvid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross ProceedsOctober 3 at 7:05 AM | globenewswire.comOvid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profileOctober 3 at 7:00 AM | globenewswire.comOvid Therapeutics (NASDAQ:OVID) Sees Large Decrease in Short InterestOctober 2 at 5:21 PM | marketbeat.comOvid Therapeutics (NASDAQ:OVID) Given Average Rating of "Buy" by BrokeragesOctober 2 at 2:44 AM | americanbankingnews.comOvid Therapeutics (NASDAQ:OVID) Given Average Recommendation of "Buy" by BrokeragesOctober 2 at 2:44 AM | marketbeat.comBiotech Stocks Rebound After Hours Amid Broader Sector Tailwinds September 30, 2025 | rttnews.comOvid Therapeutics Regains Nasdaq ComplianceSeptember 16, 2025 | msn.comOvid Therapeutics (NASDAQ:OVID) Receives Average Recommendation of "Buy" from BrokeragesSeptember 8, 2025 | marketbeat.comHC Wainwright Cuts Earnings Estimates for Ovid TherapeuticsAugust 29, 2025 | marketbeat.comAffinity Asset Advisors LLC Invests $208,000 in Ovid Therapeutics $OVIDAugust 28, 2025 | marketbeat.comLucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 TargetAugust 24, 2025 | finance.yahoo.comLucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 TargetAugust 23, 2025 | insidermonkey.comOvid Therapeutics (NASDAQ:OVID) Short Interest Up 54.8% in JulyAugust 22, 2025 | marketbeat.comSpotlight On 3 Promising Penny Stocks With Over $60M Market CapAugust 20, 2025 | uk.finance.yahoo.comWilliam Blair Predicts Higher Earnings for Ovid TherapeuticsAugust 19, 2025 | marketbeat.comQ3 EPS Estimates for Ovid Therapeutics Increased by B. RileyAugust 19, 2025 | marketbeat.comWedbush Research Analysts Lower Earnings Estimates for OVIDAugust 19, 2025 | marketbeat.comOvid Therapeutics (NASDAQ:OVID) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPSAugust 17, 2025 | marketbeat.comOvid Therapeutics (NASDAQ:OVID) Rating Increased to Hold at Wall Street ZenAugust 17, 2025 | marketbeat.comOvid Therapeutics Second Quarter 2025 Earnings: Beats ExpectationsAugust 16, 2025 | finance.yahoo.comOvid Therapeutics Reports Increased Revenue Amid ChallengesAugust 14, 2025 | msn.comOvid Therapeutics Navigates FDA Disruptions and Government ChallengesAugust 14, 2025 | tipranks.comOvid Therapeutics: Strategic Advances and Promising Developments Justify Buy RatingAugust 13, 2025 | tipranks.comOvid Therapeutics initiated with a Buy at Lucid CapitalAugust 13, 2025 | msn.comOvid Therapeutics Transfers Stock to Nasdaq Capital MarketAugust 13, 2025 | msn.comOvid Therapeutics Reports Business Updates and Second Quarter 2025 Financial ResultsAugust 13, 2025 | globenewswire.comLucid Capital Markets initiates Ovid Therapeutics stock with Buy ratingAugust 13, 2025 | investing.comAmit Rakhit: Global Access, Local Wisdom — How Biotech Thrives Amid Regulatory ComplexityAugust 13, 2025 | msn.comB.Riley assumes coverage on Ovid Therapeutics stock with Buy ratingAugust 8, 2025 | investing.comOvid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica PharmaJuly 25, 2025 | insidermonkey.comOvid Therapeutics to Participate in the BTIG Virtual Biotech ConferenceJuly 23, 2025 | globenewswire.comOvid Therapeutics management to meet with B. RileyJuly 17, 2025 | msn.comOvid Therapeutics Approves Key Proposals at Annual MeetingJuly 10, 2025 | tipranks.comOvid Therapeutics Inc. (OVID) - Yahoo FinanceJuly 8, 2025 | finance.yahoo.comOvid Therapeutics Inc Chart - MorningstarJuly 2, 2025 | morningstar.comMOvid Therapeutics To Sell Future Royalties Of Ganaxolone For $7 Mln In Cash, Stock Up In Pre-Market - NasdaqJune 27, 2025 | nasdaq.com Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OVID Media Mentions By Week OVID Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OVID News Sentiment▼0.950.54▲Average Medical News Sentiment OVID News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OVID Articles This Week▼212▲OVID Articles Average Week Get the Latest News and Ratings for OVID and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Ovid Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies RGNX News SLDB News CTMX News FULC News INBX News MNPR News GLUE News CYRX News ITOS News RAPT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OVID) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
